Swetal Patel, MD
Cardiovascular Disease · Las Vegas, NVNPI 1205253382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,470 of the $13,331 with a category attached, or 86.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 172 payments — averaging $77.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$2K
- Medtronic$2K
- Shockwave Medical, Inc$1K
- Amgen$856
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
- plus $4K from 27 others
What the payments were for
- Travel & lodging$8146%
- Food & beverage$11,47086%
- Education$1,0488%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $2,306 |
| Abiomed | 22 | $2,004 |
| Medtronic(2 entities) | 17 | $1,829 |
| Shockwave Medical, Inc | 15 | $1,355 |
| Amgen | 7 | $856 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $551 |
| E.r. Squibb & Sons, L.L.C. | 9 | $437 |
| Boston Scientific | 3 | $424 |
| Novartis | 19 | $379 |
| Asahi Intecc USA, Inc. | 3 | $367 |
| AstraZeneca | 4 | $291 |
| Cvrx, Inc. | 2 | $269 |
| Chiesi USA, Inc. | 3 | $250 |
| Cardiovascular Systems Inc. | 5 | $217 |
| Impulse Dynamics (USA) Inc. | 3 | $208 |
| Biosense Webster, Inc. | 2 | $171 |
| W. L. Gore & Associates, Inc. | 1 | $149 |
| Penumbra, Inc. | 1 | $147 |
| Kestra Medical Technology Services, Inc. | 4 | $136 |
| Actelion Pharmaceuticals US, Inc. | 1 | $132 |
| Merck | 6 | $131 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Avinger Inc. | 1 | $119 |
| Amarin Pharma, Inc. | 1 | $115 |
| Lantheus Medical Imaging, Inc. | 5 | $97 |
| Teleflex LLC | 1 | $83 |
| Cleerly, Inc. | 1 | $50 |
| Esperion Therapeutics, Inc. | 1 | $43 |
| BD | 1 | $29 |
| Philips North America LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,193
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$941
- TurboHawk$891
- AVEIR$815
- Repatha$785
- GALLANT$515
- Carto 3$490
- LifeVest$320
- Barostim Neo System$269
- ASAHI PTCA Guide Wire$264
- CAMZYOS$240
- Confirm Rx$226
- GENERAL ULTRASOUND$174
- HeartMate 3 Left Ventricular Dev$173
- Vascular Lithotripsy$172
- ENROUTE Transcarotid Neuroprotection System$157
- HawkOne$153
- CoreValve Evolut$152
- GORE CARDIOFORM Septal Occluder$149
- Indigo System$147
How this compares
$13,331 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 17 | $131,123 |
| EliquisApixaban | 90 | $112,219 |
| EntrestoSacubitril/Valsartan | 63 | $83,697 |
| FarxigaDapagliflozin Propanediol | 37 | $44,586 |
| OzempicSemaglutide | 34 | $43,143 |
| XareltoRivaroxaban | 40 | $41,412 |
| MounjaroTirzepatide | 30 | $33,457 |
| JardianceEmpagliflozin | 15 | $18,643 |
| BrilintaTicagrelor | 15 | $15,329 |
| Repatha SyringeEvolocumab | 15 | $13,964 |
| Ranolazine ErRanolazine | 46 | $3,503 |
| Metoprolol Succinate | 75 | $808 |
| Atorvastatin Calcium | 93 | $663 |
| ClopidogrelClopidogrel Bisulfate | 66 | $562 |
| Potassium Chloride | 19 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $437 | $131,12317 claims |
| PfizerEliquis | $15 | $112,21990 claims |
| NovartisEntresto | $379 | $83,69763 claims |
| AstraZenecaFarxiga, Brilinta | $291 | $59,91552 claims |
| Johnson & JohnsonXarelto | $14 | $41,41240 claims |
| Boehringer IngelheimJardiance | $14 | $18,64315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.